Source disclosure: February 13, 2026
TAIKO PHARMACEUTICAL CO.,LTD. [4574.T]
TOKYO, Feb 13 (Pulse News Wire) -- Taiko Pharmaceutical Co., Ltd. (4574.T), represented by President and CEO Takeshi Shibata, announced today that its board of directors has resolved to propose amendments to certain articles of the company's articles of incorporation at the upcoming 80th ordinary shareholders' meeting scheduled for March 27, 2026.
The proposed changes aim to address potential situations where the number of statutory audit committee members among the directors may fall short of legal requirements. Specifically, Article 19 of the amended proposal will introduce a new paragraph four, allowing the company to appoint substitute audit committee members through shareholder resolutions when necessary. Additionally, the amendment seeks to align the validity period of such resolutions with the term of office of the audit committee members. To achieve this, a new paragraph four is also being added under Article 20, stipulating that any resolution concerning the appointment of substitute audit committee members shall remain effective until the opening of the regular shareholders' meeting held within two years after the end of the relevant fiscal year.
The detailed amendments include the addition of new provisions as follows: - Under Article 19 (Selection Method): A fourth paragraph will be newly established, granting the authority to select substitute audit committee members via shareholder resolutions in cases where the required number of statutory audit committee members is insufficient. - Under Article 20 (Term): Similarly, a fourth paragraph will be introduced, setting the duration during which decisions on appointing substitute audit committee members will retain their effectiveness up to the start time of the regular shareholders' meeting concluding the second fiscal year post-resolution.
These modifications are set to take effect upon approval at the shareholders' meeting slated for March 27, 2026, marking an important step towards ensuring robust governance practices within the corporation.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing